Filgrastim Completed Phase 2 Trials for Neutropenias / Cancer, Breast Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00665457Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00072319Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00020176Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
NCT00007904Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
NCT00015938S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
NCT00041067S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
NCT00005800Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
NCT00004906Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00004900Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00003953Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
NCT00004172Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
NCT00004092Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00002679Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
NCT00002680Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer
NCT00003035Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
NCT00003392High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
NCT00497809Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
NCT02521441A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.